Condition 1: Rate of apoptosis (cell death). Condition 2: Gene expression changes. Condition 3: Entrance Skin Dose. Condition 4: Dose Length Product.
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Age range over 18 years old Having informed consent Referred for CT scan
Exclusion criteria
Exclusion criteria: Known allergy to the study drug Use of progestin-based medications, herbal sedatives, 5 HTP supplements, blood thinners (such as warfarin, heparin), blood pressure medications (especially nifedipine), medications that may affect the immune system (such as azathioprine, cyclosporine, prednisone), sleeping pills or anti-anxiety medications (such as diazepam, alprazolam), antihistamines (such as cetirizine, diphenhydramine), muscle relaxants and pain relievers (such as codeine), fluvoxamine Undergoing surgery, chemotherapy, or radiotherapy within one month prior to the study Having a CT scan one month before the study Having an active viral infection within one week before the imaging procedure Having seizures and convulsive diseases Being pregnant Being breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Apoptosis (cell death). Timepoint: 30 minutes before the intervention and 24 hours after the test. Method of measurement: Counting the number of apoptotic peripheral blood lymphocytes by flow cytometry.;Gene expression changes. Timepoint: 30 minutes before the intervention and 24 hours after the test. Method of measurement: Real-Time PCR.;Entrance Skin Dose (ESD). Timepoint: When performing a CT scan. Method of measurement: Thermoluminescent Dosimeter (TLD).;Dose length Product (DLP). Timepoint: after a CT scan. Method of measurement: Measurement using information on the CT scan machine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: All patients are given a phone number to call in case of emergency, while taking melatonin and for 24-48 hours afterwards if needed, to report any side effects caused by the medication. Method of measurement: Control by a specialist physician and radiologist present in the plan.;Reducing the risk of cancer. Timepoint: After sampling is completed. Method of measurement: Based on data collected from patients CT scan and using IMPACT software. | — |
Countries
Iran (Islamic Republic of)
Contacts
Shahid Beheshti University of Medical Sciences